In recent years, the rising prevalence of respiratory diseases, coupled with advancements in biotechnology and pharmacology, has positioned inhalable formulations as a preferred method of drug administration. This approach enables direct and rapid delivery of medication to the lungs, maximizing therapeutic effects while minimizing dosage and potential side effects. In this review, we meticulously examined current literature and clinical trial databases to present a comprehensive overview of three key areas: (1) inhalation devices currently utilized in clinical settings; (2) the clinical applications of approved inhalable formulations; and (3) preclinical research on inhalable treatments targeting various lung conditions, including pulmonary infections, tuberculosis, lung cancer, pulmonary fibrosis, as well as systemic diseases like Parkinson’s disease. The objective was to delve into both foundational research and the clinical use of inhalable formulations within the pharmaceutical field, with the aim of fostering their broader adoption and guiding the development of inhalable therapies for a more comprehensive range of diseases.
>
>